The interferon-NUB1-p27Kip1-ERα pathway we propose provides a plausible mechanism for FEC’s differential effects in ER+ versus ER− BC cell lines, warranting further investigation into this pathway’s therapeutic potential. The gene discussed is CDKN1B; the disease is breast cancer.